Long-term remission with rituximab in refractory leucine-rich glioma inactivated 1 antibody encephalitis

Autoimmune encephalitis associated with antibodies to leucine-rich glioma inactivated 1 (LGI1) is recently described and there is a lack of detailed reports on the treatment of relapsing or refractory cases and long-term outcomes. Two case reports are presented. Both cases had faciobrachial dystonic...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of neuroimmunology Vol. 271; no. 1-2; pp. 66 - 68
Main Authors:	Brown, J. William L., Martin, Peter J., Thorpe, John W., Michell, Andrew W., Coles, Alasdair J., Cox, Amanda L., Vincent, Angela, Zandi, Michael S.
Format:	Journal Article
Language:	English
Published:	Netherlands Elsevier B.V 15.06.2014
Subjects:	Adult Aged Allergy and Immunology Antibodies - blood Antibodies, Monoclonal, Murine-Derived - therapeutic use Autoantibody Cognition Encephalitis Encephalitis - blood Encephalitis - drug therapy Encephalitis - immunology Female Humans Immunologic Factors - therapeutic use LGI1 Male Neurology Proteins - immunology Rituximab Secondary Prevention Seizures - drug therapy Treatment Outcome VGKC LGI1 Autoantibody Rituximab VGKC Encephalitis Cognition
ISSN:	0165-5728, 1872-8421, 1872-8421
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!